Total pharma M&A deals for January 2019 worth $91.23bn were announced in the United States, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 1436.3% over the previous month and a rise of 1488.8% when compared with the last 12-month average of $5.74bn.

The United States held a 99.1% share of the global pharma M&A deal value that touched $92.08bn in January 2019.

In terms of deal activity, the United States recorded 28 deals during January 2019, marking an increase of 100% over the previous month and a rise of 47.4% over the 12-month average.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pharma M&A deals for January 2019: Top deals

The top five pharma M&A deals accounted for 99.99% of the overall value in the sector globally during January 2019.

The combined value of the top five pharma M&A deals stood at $91.21bn, against the overall value of $91.23bn recorded for the month. The top announced pharma M&A deal tracked by GlobalData in January 2019 was Bristol-Myers Squibb‘s $82.83bn acquisition of Celgene.

In second place was Eli Lilly’s acquisition of Loxo Oncology for $8bn and in third place was Acrotech Biopharma’s $300m acquisition of Spectrum Pharmaceuticals.

ProKidney’s $62m acquisition with inRegen and Aldeyra Therapeutics’ acquisition of Helio Vision for $25m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

Verdict’s parent company GlobalData plc provides business information to 4,000 of the world’s largest companies.